Evolution of the Average Target: DSM-Firmenich

Evolution of the Average Target - DSM-Firmenich

Evolution of the Target Price: DSM-Firmenich

Evolution of the Target Price - DSM-Firmenich

Changes in Analyst Recommendations: DSM-Firmenich

5873b3809f7ff7bae6ed0c5137006.nMfofwOZgDR3B0uqVP0r27qgp-8uMg09BBx2jS1x6O8.976AK0DI-VwlbXnEPrdKt_bzyKIDd0p6aUkF_14Dj6TQn4UYQda2VjhgJA~904ed45378b1d67d700c33eb1f58aeb2
10-07 EU contemplates changes to agri-chemical regulations Alphavalue
09-08 Rothschild & Co. Redburn Downgrades DSM-Firmenich to Neutral, Trims PT MT
08-18 KBC Securities Downgrades DSM-Firmenich to Hold MT
08-12 Kempen Downgrades DSM-Firmenich to Sell, Boosts PT MT
08-10 Oddo BHF Boosts DSM-Firmenich PT, Maintains Outperform Rating MT
08-06 Equita SIM Downgrades DSM-Firmenich to Hold, Raises PT MT
07-30 DSM-Firmenich: Volume inflection validated the strategy Alphavalue
06-19 AlphaValue/Baader Europe Downgrades DSM-Firmenich to Reduce, Lifts PT MT
06-09 AlphaValue/Baader Europe Upgrades DSM-Firmenich to Add, Lifts PT MT
06-08 Goldman Sachs Downgrades DSM-Firmenich to Sell, Cuts PT MT
05-22 AlphaValue/Baader Europe Downgrades DSM-Firmenich to Reduce, Lifts PT MT
05-22 Swiss stocks - Factors to watch on May 22 RE
05-06 DSM-Firmenich: Volumes deliver, margin to follow Alphavalue
04-28 KBC Securities weighs in on DSM-Firmenich divestment Zonebourse
03-18 KBC Securities Still Positive on DSM-Firmenich Zonebourse
03-17 Sulfur and methanol prices soar on Middle East conflict Alphavalue
03-13 DSM-Firmenich ready to step up the pace and hit its mid-term targets Zonebourse
03-12 DSM-Firmenich: The story moves from restructuring to delivery Alphavalue
03-11 Kempen Downgrades DSM-Firmenich to Neutral, Cuts PT MT
03-04 Middle East tensions intensify pessimism in chemicals Alphavalue
02-26 AlphaValue/Baader Europe Adjusts Rating, Estimates for DSM-Firmenich on Sale of Animal Nutrition, Health Unit MT
02-25 DSM-Firmenich: ANH Divestment at a Discount May Unlock Growth Potential Alphavalue
02-13 Kepler Cheuvreux Downgrades DSM-Firmenich to Hold, Cuts PT MT
02-12 DSM-Firmenich: Profitability disappoints in FY25 Alphavalue
02-09 DSM-FIRMENICH : Jefferies reaffirms its Buy rating ZD

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-4.12%
+5.21%
+16.83%
+15.51%
+43.02%
+14.79%
+28.92%
+24.1%
- - -8.71%
Average +15.06%
Weighted average by Cap. +10.54%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
97.90EUR
Average target price
96.02EUR
Spread / Average Target
-1.92%
High Price Target
117.00EUR
Spread / Highest target
+19.51%
Low Price Target
68.00EUR
Spread / Lowest Target
-30.54%

Analyst Consensus Detail

Analyst consensus - DSM-Firmenich

Consensus revision (last 18 months)

Consensus revision (last 18 months) - DSM-Firmenich
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - DSM-Firmenich
  1. Stock Market
  2. Stocks
  3. DSFIR Stock
  4. Consensus DSM-Firmenich